Study guide

16.3 Agitated Saline Bubble Studies, Ultrasound Enhancing Agents & Shunt Timing

ARDMS Pediatric Echocardiography RDCS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Normal Great Arteries & Coronary Origins

1.1 Aortic Arch, Branching Patterns & Conotruncal Anatomy 1.2 Normal Coronary Artery Anatomy, Origins & Variants 1.3 Pulmonary Artery Branching & Ductus Arteriosus Geometry

2 Chapter 2: Systemic and Pulmonary Veins & Cardiac Chambers

2.1 Systemic Venous Connections: IVC, SVC, Hepatic Veins & Coronary Sinus 2.2 Pulmonary Venous Drainage, Left Atrium & Ridge Anatomy 2.3 Right and Left Ventricular Anatomy & Morphologic Characteristics

3 Chapter 3: Cardiac Valves, Transitional Circulation & Situs

3.1 Atrioventricular and Semilunar Valve Morphology & Subvalvular Apparatus 3.2 Fetal to Neonatal Transitional Circulation, Persistent Fetal Shunts & Visceral Situs

4 Chapter 4: Pediatric Cardiomyopathies & Cardiotoxicity

4.1 Hypertrophic and Restrictive Cardiomyopathy in Children 4.2 Dilated, Non-Compaction & Arrhythmogenic Ventricular Cardiomyopathies 4.3 Anthracycline Cardiotoxicity, Neuromuscular Dystrophies & Metabolic Infiltration

5 Chapter 5: Inflammatory, Hypertensive & Systemic Acquired Conditions

5.1 Kawasaki Disease & Pediatric Coronary Aneurysm Surveillance 5.2 Infective Endocarditis, Rheumatic Heart Disease & Pericardial Effusion 5.3 Pediatric Pulmonary Arterial Hypertension, Cor Pulmonale & Eisenmenger Syndrome 5.4 Systemic Hypertension & Hypertensive Heart Disease in Children 5.5 Heritable Connective Tissue Disorders & Pediatric Aortopathy

6 Chapter 6: Septal Defects & Atrioventricular Canal Anomalies

6.1 Atrial Septal Defects: Secundum, Primum, Sinus Venosus & Unroofed Coronary Sinus 6.2 Ventricular Septal Defects: Membranous, Muscular, Inlet & Malalignment 6.3 Complete, Partial & Transitional Atrioventricular Canal (AV Septal) Defects

7 Chapter 7: Conotruncal Anomalies & Outflow Malformations

7.1 Tetralogy of Fallot, Absent Pulmonary Valve & Pulmonary Atresia with VSD 7.2 D-Transposition of the Great Arteries & L-Transposition (ccTGA) 7.3 Truncus Arteriosus, Double Outlet Right Ventricle (DORV) & Aortopulmonary Window

8 Chapter 8: Left and Right Heart Obstructive & Valvular Defects

8.1 Coarctation of the Aorta, Interrupted Aortic Arch & Shone Complex 8.2 Aortic Valve Stenosis, Subaortic Membranes, Supravalvular AS & Bicuspid Aorta 8.3 Ebstein Anomaly, Tricuspid Dysplasia & Congenital Pulmonary Stenosis/Atresia

9 Chapter 9: Venous & Ductal Anomalies, Coronaries, Single Ventricle, Cardiac Masses & Genetic Syndromes

9.1 Total & Partial Anomalous Pulmonary Venous Connection (TAPVC/PAPVC) 9.2 Patent Ductus Arteriosus & Vascular Rings / Slings 9.3 Anomalous Coronary Origins: ALCAPA, ARCAPA, Course & Fistulas 9.4 Hypoplastic Left Heart Syndrome (HLHS) & Tricuspid Atresia Anatomy 9.5 Cardiac Tumors & Intracardiac Masses in Children 9.6 Cor Triatriatum, Systemic Venous Anomalies & Heterotaxy Syndromes 9.7 Genetic Syndromes & Their Associated Cardiac Lesions

10 Chapter 10: Surgical Repair of Septal Defects, TOF & Arch Lesions

10.1 Postoperative ASD, VSD & AV Canal Repair Assessment 10.2 Postoperative Tetralogy of Fallot Repair & Pulmonary Valve Replacement 10.3 Postoperative Coarctation Repair, Arch Reconstruction & Residual Gradients

11 Chapter 11: Great Artery Switches, Baffles & Conduit Operations

11.1 Arterial Switch Operation (Jatene) & Lecompte Maneuver Evaluation 11.2 Atrial Inversion Baffles (Mustard/Senning) & Rastelli Repair 11.3 Right Ventricle to Pulmonary Artery (RV-PA) Conduits & Ross Procedure

12 Chapter 12: Single Ventricle Palliation, TAPVC Repair, Transplants & Devices

12.1 Norwood Stage I Reconstruction, Sano Shunts & Blalock-Taussig Shunts 12.2 Superior Cavopulmonary Connection (Bidirectional Glenn / Hemi-Fontan) 12.3 Total Cavopulmonary Connection (Fontan Completion: Extracardiac & Lateral Tunnel) 12.4 Postoperative TAPVC Repair, Pediatric Heart Transplantation & Ventricular Assist Devices 12.5 Implantable Devices, Lines & Lead-Related Echocardiographic Findings 12.6 Transcatheter Interventions: Balloon Valvuloplasty, Stents & Valve Implantation

13 Chapter 13: Acoustic Windows, Instrumentation & Pediatric Ergonomics

13.1 Standard Pediatric Acoustic Windows & Subcostal / Suprasternal Views 13.2 Transducer Selection, High Frequency Probes, Frame Rates & Pediatric Ergonomics 13.3 Patient Immobilization, Pediatric Sedation Protocols & Safety Considerations

14 Chapter 14: Doppler Hemodynamics, Bernoulli & Shunt Evaluation

14.1 Modified Bernoulli Equation, Peak vs Mean Gradients & Continuity Equation 14.2 Pulmonary-to-Systemic Flow Ratio (Qp:Qs) Calculations & Shunt Direction 14.3 Right Ventricular Systolic Pressure (RVSP) & Pulmonary Artery Pressure Estimation

15 Chapter 15: Chamber Quantification, Systolic & Diastolic Assessment

15.1 Pediatric Z-Score Methodology & BSA Indexing (Haycock/DuBois) 15.2 Left Ventricular Systolic Function: Simpson Biplane, 5/6 Area x Length & FS 15.3 Right Ventricular Quantitative Function: TAPSE, FAC & Tissue Doppler S' 15.4 Pediatric Diastolic Function Assessment: Mitral Inflow, Tissue Doppler & E/e'

16 Chapter 16: Advanced Modalities: Strain, 3D Echo & Saline Studies

16.1 Speckle Tracking Echocardiography & Global Longitudinal Strain (GLS) 16.2 Real-Time 3D Pediatric Echocardiography: En Face Valvular Imaging & Volume Assessment 16.3 Agitated Saline Bubble Studies, Ultrasound Enhancing Agents & Shunt Timing 16.4 Transesophageal (TEE) & Epicardial Echocardiography in Congenital Heart Surgery

16.3 Agitated Saline Bubble Studies, Ultrasound Enhancing Agents & Shunt Timing

Key Takeaways Explain This Topic AI

Agitated saline investigates right-to-left passage and systemic venous drainage, whereas manufactured UEAs can cross the normal pulmonary circulation for left-heart enhancement. Their left-heart appearances cannot be interpreted with one interchangeable shunt-timing rule.

Use an established clinical preparation, access, imaging and monitoring protocol appropriate to the patient and circulation. ASE describes optional blood in preparation methods; syringe capacity, mixture components and injected volume are different quantities, not a universal infant dose.

For the usual adequately RA-opacifying route, ASE 2024 describes 3–6 cycles after RA opacification as suggesting interatrial passage and later than 6 as suggesting pulmonary passage. These are conditional clues: anatomical septal crossing or pulmonary-vein entry and actual circulation can outweigh a generic timing shortcut.

Ventricular filling pressure, streaming, opacification, imaging and maneuver adequacy affect a negative study. A suitable left-arm injection can show left-SVC-to-coronary-sinus drainage; a Glenn first pass or anomalous venous pathway changes which structures and timing reference are relevant.

Current US Lumason labeling includes a pediatric LV-opacification indication and retains product-specific cardiopulmonary, hypersensitivity and shunt warnings. Check the exact agent, indication, current jurisdictional label and imaging method; neither blanket pediatric off-label status nor universal administration/settings is correct.

Last updated: October 2026

16.3 Agitated Saline Bubble Studies & Shunt Localization

Clinical Core: Agitated saline contrast can help identify intracardiac or intrapulmonary right-to-left passage and abnormal systemic venous drainage. Interpretation combines the injection route, adequately opacified structures, anatomical entry site, timing, pressure/flow conditions and image quality . A fixed beat count is not a definitive diagnosis. In particular, a surgically altered venous route may bypass the RA, making an ordinary RA-based timing rule inapplicable to that first pass.

Physical Principle and the Question Being Asked

Agitated saline produces echogenic microbubbles that ordinarily do not pass through the normal pulmonary capillary circulation in the same way as a manufactured ultrasound enhancing agent. The resulting contrast can outline venous/right-heart pathways and demonstrate passage toward the systemic circulation. The study is interpreted from the observed pathway, not from an assumed universal microbubble diameter or a claim that every injection creates an identical size distribution. Usual systemic venous route

  • Peripheral vein → Systemic vein → RA → RV → Pulmonary arteries → Lung circuit
  • │
  • └→ Possible interatrial right-to-left passage

Potential pulmonary passage → Pulmonary veins → LA

This drawing assumes usual connections. A left SVC, systemic-to-pulmonary venous collateral, atrial switch baffle or cavopulmonary connection can change where the injected contrast appears first. Start by defining the clinical question: a suspected interatrial route, a pulmonary route, left SVC drainage, an unroofed coronary sinus or a postoperative communication are different questions.

Agitated saline is especially useful for right-to-left passage . It is not a substitute for 2D/color assessment of a predominantly left-to-right ASD. An ASD can be anatomically present even if the saline study does not demonstrate right-to-left crossing during the observed conditions.

Protocol Components: Laboratory Method, Not a Universal Pediatric Recipe

The ASE 2024 pediatric TTE guideline recommends an established protocol that addresses indication, access site, imaging, preparation, injection and interpretation. It describes published preparation methods and a suggested protocol table. Those descriptions are not a universal patient dose or permission to ignore age, size, access, circulation or local clinical requirements.

What Must Be Defined Before Interpretation

Indication and anatomy: Identify the suspected route and relevant surgical/venous connections. Know whether the injected vein returns through a right SVC, a left SVC, a cavopulmonary pathway or another connection.

Access and preparation: Use the approved laboratory method with trained personnel and appropriate clinical oversight. The guideline describes two connected syringes and an agitated saline mixture, with a small amount of air and optional patient blood. Container capacity, component volumes and injected volume are different quantities; a fixed adult preparation must not be converted into an automatic infant bolus.

Imaging and recording: Obtain a view that includes the structures needed to see the suspected crossing or venous entry. Apical four-chamber and subcostal coronal views are commonly used. Harmonic imaging can improve contrast visibility. Record a sufficiently long clip to assess the actual first pass and subsequent appearance, following the protocol.

Adequacy: Determine whether the intended venous/right-heart structures were adequately opacified and whether the relevant septum or venous entry was visible. A technically inadequate study is not equivalent to a negative study.

Physiology and maneuver: Record rest versus provocation, respiratory/ventilation conditions and whether the maneuver actually changed the interatrial pressure relationship when that is the question.

Blood is not a mandatory ingredient in every protocol: ASE describes it as optional/if available. Do not teach that one fixed aliquot is essential, that it always produces a specified bubble diameter or that it multiplies bubble concentration by a universal factor. The relevant endpoint is a suitable, safely prepared study with interpretable opacification under the clinical protocol.

Interatrial Pressure and Provocation

A PFO is an overlapping flap/tunnel. Higher LA than RA pressure commonly tends to keep the flap closed, while a temporary reversal can permit right-to-left flow. The effect depends on the actual pressure relationship and septal anatomy, rather than a required resting pressure pair or a predictable RA pressure spike in every child.

Resting and Provoked Studies

A study can be performed at rest and, when clinically appropriate, with a protocol-directed maneuver. ASE 2024 notes that Valsalva or gentle abdominal pressure may help when an initial study is negative; a leftward septal shift can demonstrate that the intended pressure change occurred. The timing and feasibility of a maneuver depend on the patient and protocol.

Valsalva release can increase venous return and favor transient right-to-left passage, but an observed release does not guarantee that RA pressure exceeded LA pressure or that a PFO opened. Cooperative children, infants, ventilated patients and patients with elevated filling pressures cannot all be assessed with one rigid “strain for a fixed number of seconds, inject at a fixed second” prescription.

Document the maneuver and its adequacy. If the intended pressure reversal was not achieved, state that limitation. Do not label every resting-negative/provoked-positive examination as the same shunt size, and do not equate an unsuccessful maneuver with an absent communication.

Why a Negative Result Can Mislead

Elevated LA pressure can prevent demonstrable interatrial right-to-left passage.

A prominent Eustachian valve or other streaming pattern can direct IVC blood toward the septum while SVC-injected contrast follows a different path.

Poor opacification, limited visualization or an insufficient recording can conceal the relevant entry.

A postoperative or anomalous venous connection can send contrast through a route different from the one assumed by the observer.

ASE also describes a possible false-positive interpretation after release of pooled pulmonary venous blood following prolonged Valsalva. These examples explain why the pathway and study quality matter alongside the timing.

Timing in the Usual RA-Opacifying Circulation

For the usual systemic venous pathway with adequate RA opacification, ASE 2024 pediatric guidance describes:

LA/left-heart contrast within 3–6 cardiac cycles after RA opacification as suggesting interatrial shunting.

LA contrast later than 6 cardiac cycles after RA opacification as raising suspicion for intrapulmonary shunting.

These are conditional clues. They are not mutually exclusive bins that prove a lesion, exclude every alternative or apply unchanged to every cardiac output, maneuver, imaging method or congenital/postoperative circulation. “Cycle zero” refers to the observed RA opacification in this usual-route interpretation, not the time the syringe was handled or the first contrast anywhere in an altered circuit.

Direct Septal Crossing

If contrast is seen crossing the atrial septum, describe the location and conditions. A PFO flap, secundum defect, unroofed coronary sinus and postoperative baffle leak have different anatomic boundaries. Do not name the route merely because contrast appeared early somewhere on the left side.

An apparent defect in an apical view may be dropout. Confirm actual anatomy and flow in additional planes, often with the septum more perpendicular to the ultrasound beam. A single frame or one bright focus is not a complete demonstration of a communication.

Pulmonary Venous Entry

Contrast emerging from pulmonary veins supports a pulmonary route when the injection pathway and circulation are understood. The observed entry can be more informative than forcing a beat count into an old generic cutoff. For example, pulmonary venous entry during the fifth cycle should not automatically be relabeled a PFO solely because it falls inside the guideline's usual 3–6-cycle interatrial clue.

Conversely, the failure to see contrast cross the septum is not by itself proof of pulmonary passage. The septum may have been poorly seen, and an abnormal systemic venous channel may provide another route. Identify positive evidence for the pathway and report uncertainty when it cannot be resolved.

Describing Amount Without Mixing Grading Systems

Record the extent of opacification, reproducibility, rest/provocation conditions and the laboratory's defined scale when a shunt grade is used. Published protocols and clinical studies use different bubble counts, image grades and acquisition methods. Do not present one 1–9/10–30/>30 table as a universal pediatric standard or interchange a count in one frame with a diagnosis or lesion diameter.

The qualitative contrast appearance is also affected by preparation, venous access, gain, image settings and hemodynamics. A denser image does not automatically mean a larger anatomical defect. State the grading method so a later study can be compared meaningfully.

  • Circulation-Specific Localization
  • 1. Intracardiac Interatrial Passage

Demonstrate contrast at the relevant septal region and correlate it with 2D/color anatomy. A PFO can allow intermittent passage during appropriate pressure reversal, while a true ASD may have predominantly left-to-right flow and show little or no saline crossing under the observed conditions. Define the actual atrial morphology and shunt direction rather than assuming all ASDs behave identically.

If a different intracardiac route is suspected, trace its chambers and pressure relationship. The usual interatrial timing statement is not a universal diagnostic test for every VSD, single-ventricle communication or baffle defect.

2. Intrapulmonary Passage and Clinical Context

Pulmonary arteriovenous communications or vascular dilatation can permit contrast to reach the systemic atrium through pulmonary veins. Potential settings include congenital vascular disorders, liver-associated pulmonary vascular disease and cavopulmonary palliation.

In a patient with liver disease and hypoxemia, demonstrated intrapulmonary passage supports evaluation for hepatopulmonary syndrome. Timing alone is not “pathognomonic,” and one contrast observation does not replace the other clinical diagnostic requirements. Similarly, a positive pulmonary route does not determine whether the communication is a discrete treatable lesion, a diffuse process or part of a different condition.

3. Post-Glenn and Fontan Pathways

After a Glenn, an upper-extremity injection into a connected SVC can reach the PA/lung circuit without first opacifying the RA . A lower-extremity injection may instead reach the atrial/ventricular circulation directly before Fontan completion. After Fontan completion, the systemic venous pathways and a possible fenestration create another pattern. Interrupted IVC, bilateral SVCs and collateral channels add further variation.

Therefore, do not diagnose PAVMs after surgery from a universal “3–5 beats,” “4–6 beats,” or substituted “>6 beats” rule. Define the injection site and first-pass route, look for pulmonary-vein entry and assess competing systemic venous collateral or fenestration pathways. The ordinary RA-based clock only applies if the required RA-opacifying route is actually present and relevant.

Reduced or unequal hepatic venous exposure is associated with pulmonary arteriovenous abnormalities in cavopulmonary circulations. The hepatic-factor concept describes an incompletely understood mechanism, not a proven single substance whose absence can be diagnosed from one contrast clip. A primary Fontan cohort illustrates the importance of circulation-specific contrast assessment and distinguishing pulmonary communications from veno-venous collaterals; its methods or grading are not a universal bedside protocol.

4. Persistent Left SVC and Coronary Sinus Drainage

When a left SVC draining to the coronary sinus is suspected, a clinically appropriate left upper-extremity injection can opacify the coronary sinus before the RA. This supports that venous drainage pattern. Trace the anatomy and consider bilateral SVCs and a connecting vein; a right-arm injection may follow a right SVC and fail to answer the left-sided question.

An unroofed coronary sinus provides communication between the coronary sinus and LA. ASE 2024 describes left superior systemic venous injection with coronary sinus contrast followed by simultaneous RA and LA opacification as a supporting pattern. Direct LA appearance also requires assessment of other left-sided venous drainage possibilities. Do not make one negative injection a definitive exclusion of every left SVC or call every direct LA appearance an unroofed coronary sinus without defining the connection.

5. Atrial Switch Baffle Leaks

After Mustard/Senning repair, systemic venous blood is directed toward the subpulmonary morphologic LV, while pulmonary venous blood reaches the systemic morphologic RV. Contrast can help demonstrate a communication between the baffle pathways when its injection and recording follow the relevant route.

Describe where the contrast crosses, direction of passage and associated physiology. A baffle leak can contribute to desaturation or paradoxical embolic risk, but early systemic contrast does not automatically establish one leak location or its clinical significance. Evaluate baffle obstruction and alternate venous routes as part of the postoperative study.

Interpretation Reference

Question Useful observation What the observation does not prove by itself

Interatrial passage in usual anatomy Direct septal crossing; ASE 2024 usual-route 3–6-cycle clue after RA opacification Exact lesion type, anatomical size or a universal shunt grade

Pulmonary passage in usual anatomy Pulmonary-vein entry; later-than-6-cycle RA-based clue Hepatopulmonary syndrome, HHT or a particular PAVM etiology without clinical correlation

Left SVC to coronary sinus Left-arm contrast reaches CS before RA Absence of all other venous anomalies, or exclusion after a technically negative injection

Unroofed coronary sinus Defined CS–LA communication and the appropriate contrast sequence That every direct LA contrast appearance has this cause

Post-Glenn pulmonary route Known SVC-to-PA first pass and systemic entry through pulmonary veins A diagnosis from an ordinary RA clock when the injection bypasses RA

Post-Fontan systemic entry Defined venous pathway, fenestration/collateral or pulmonary route That every early or late systemic contrast pattern is a PAVM

Baffle communication Contrast crossing a demonstrated postoperative baffle boundary One fixed transit count as a universal leak criterion

Safety, Documentation and Exam Traps

An agitated saline study belongs within an established clinical protocol with appropriate indication, preparation, access verification and trained personnel. Preventing unintended macroscopic air injection is a different issue from producing the intended microbubble contrast. A certification reference should not replace the laboratory's patient-specific preparation or monitoring instructions with an unsourced universal recipe.

Document the agent/technique, injection site, circulation, adequacy of opacification, maneuver, observed entry route, timing reference and clinical interpretation. If the procedure is limited, say which question remains unresolved. Contrast that follows an unexpected route should prompt anatomical review, rather than an automatic disease label.

Timing trap: “Bubbles appeared on the left” is incomplete. Ask where they entered, from which injection pathway and relative to which chamber's opacification. Negative-study trap: Failure to demonstrate right-to-left passage does not erase a known left-to-right communication. Postoperative trap: Read the reconstructed flow map before borrowing a timing rule from a usual biventricular circulation.

Agent trap: Manufactured UEAs can cross the normal pulmonary circulation and opacify the LV. Their left-heart appearance must not be interpreted using the agitated-saline shunt clock. Pediatric indications, equipment settings and warnings are product-specific; the adjacent UEA reference addresses that distinction.

Source: ASE 2024 comprehensive pediatric TTE guideline, agitated saline discussion and Table 13 . The 3–6 and >6 statements here retain its RA-opacification condition and “suggests/likely” scope; they are not a promise of definitive localization from timing alone.

Loading diagram...

Manufactured Ultrasound Enhancing Agents

Agitated saline and manufactured ultrasound enhancing agents (UEAs) are both used in contrast echocardiography, but they answer different questions. The PE outline includes UEAs among advanced ultrasound techniques. The important distinction is pulmonary transit and intended imaging purpose, not a claim that every contrast product has identical behavior, administration or regulatory status.

Composition and Pulmonary Transit

A UEA contains manufactured gas-filled microspheres stabilized by an agent-specific membrane, such as a phospholipid or protein shell. These microspheres can pass through the normal pulmonary circulation and enhance left-heart imaging. Agitated saline contrast is used differently to investigate right-to-left passage or venous drainage.

Feature Agitated saline Manufactured UEA

Physical preparation Agitated saline mixture under the laboratory protocol Product-specific manufactured microspheres, prepared according to its label

Pulmonary transit Ordinarily excluded from the normal pulmonary capillary route in the intended saline study Can traverse the normal lung circulation to opacify the LV

Main echo question Right-to-left pathway or abnormal venous drainage Improved LV cavity/endocardial-border visualization when appropriate

Left-heart appearance Interpret the actual route, adequate opacification and conditional timing Expected pulmonary transit can itself produce LV enhancement

Timing rule ASE 2024 usual-route clues require an RA-opacification reference Do not borrow the agitated-saline shunt clock to diagnose a shunt from UEA LV appearance

Brand examples include Definity, Optison and Lumason, with different formulations/components and jurisdictional labels. They are not interchangeable simply because all can enhance an ultrasound image. Confirm the exact product and its current prescribing information before drawing conclusions about indications, preparation, dosing, route or warnings.

For agitated saline in the usual RA-opacifying circulation, ASE 2024 describes 3–6 cycles after RA opacification as suggesting interatrial passage and later than 6 cycles as raising suspicion for pulmonary passage. These remain conditional clues. They do not apply unchanged to a UEA, a Glenn first-pass route or every anomalous venous connection. UEA passage into the LV is not proof of an abnormal saline right-to-left route.

Pediatric Indications: Product and Jurisdiction Matter

The blanket statement that pediatric cardiac UEA use is always off-label is incorrect. The current United States Lumason prescribing information, revised September 2026 , includes adult and pediatric patients with suboptimal echocardiograms for LV chamber opacification and improved LV endocardial-border delineation. ASE's 2024 pediatric TTE guideline also explicitly lists Lumason's approved pediatric LV-opacification indication.

That indication does not approve every possible contrast-assisted pediatric application, every agent or every jurisdiction. ASE discusses additional uses such as intracardiac mass assessment, apical hypertrophic cardiomyopathy, LV noncompaction and myocardial perfusion; the clinical team must distinguish an agent's labeled indication from another clinically selected use. A broad statement about “most jurisdictions” cannot replace checking the applicable local label.

What Enhanced Images Can Add

LV border definition: Better delineation can improve cavity tracing when native images are suboptimal. Check that enhancement reveals the actual endocardium rather than blooming beyond it. The selected ventricular method still requires suitable views and appropriate geometry.

Mass assessment: Enhancement or a filling defect can contribute to characterization. Neither a dark filling defect nor enhancement alone proves a particular histology; integrate the location, attachment, motion and other imaging.

Apical anatomy: Improved cavity visualization can help separate trabeculation, an apical structure and an incompletely defined border. It does not eliminate the need for diagnostic criteria and clinical context.

Doppler enhancement: A stronger envelope may be helpful in selected circumstances, but gain and contrast effects can alter its apparent edge. A brighter signal does not automatically justify tracing an artifact or accepting an implausible velocity.

Imaging Settings and Artifacts

Use the contrast-specific imaging method and mechanical-index settings appropriate to the product, machine, patient and clinical protocol. There is no single universal mechanical-index or infusion instruction for every pediatric UEA study. In particular, an adult infusion approach should not be copied into a pediatric protocol without checking the exact label and order.

Artifact or limitation Possible appearance Interpretive response

Bubble destruction or incomplete filling Dark or swirling portions of the cavity Reassess the imaging mode, exposure and delivery under the approved protocol

Attenuation Strong near-field contrast with poor visualization deeper in the image Recognize that excessive attenuation can conceal the border rather than define it

Blooming Signal appears beyond the true cavity boundary Optimize the image before tracing; do not accept the outer bright fringe as endocardium

Unchanged poor geometry Enhanced cavity remains foreshortened or inadequately sampled Contrast does not repair an unsuitable acquisition plane or invalidate a method's assumptions

Product-Specific Safety Context

Current U.S. Lumason labeling retains a boxed warning for uncommon serious cardiopulmonary reactions and calls for appropriate resuscitation personnel/equipment and monitoring for acute reactions. Its contraindication is known or suspected hypersensitivity to the product or its components, including PEG. Other UEAs have their own components and instructions; do not combine perflutren, sulfur hexafluoride, albumin and PEG into one universal contraindication list for every product.

The current Lumason label treats cardiac shunts in its systemic-embolization warning: microspheres can bypass pulmonary filtering, and affected patients should be assessed for embolic phenomena. A shunt warning is not the same as an absolute contraindication, and the presence of an approved pediatric indication is not a guarantee of risk-free administration.

For exam interpretation, keep three decisions separate: what imaging question is being asked, whether the selected product/use is appropriate, and what the observed contrast route actually demonstrates . A UEA can improve LV imaging while its expected left-heart appearance provides no basis for applying a saline timing shortcut.

Sources: ASE 2024 pediatric TTE discussion and Table 13 and current U.S. Lumason prescribing information , particularly Indications, Pediatric Use, Contraindications and Warnings. Approval and safety statements here retain their product, indication and jurisdictional scope.